SAR405: Selective ATP-Competitive Vps34 Inhibitor for Precision Autophagy Inhibition

Executive Summary: SAR405 (A8883) is a highly selective ATP-competitive inhibitor of class III phosphoinositide 3-kinase (Vps34) with a Kd of 1.5 nM and IC50 of 1 nM for the human recombinant enzyme. It does not inhibit class I/II PI3Ks or mTOR up to 10 μM, enabling targeted autophagy inhibition and vesicle trafficking modulation in vitro. SAR405 blocks autophagosome formation and disrupts endosome-lysosome function, making it a robust tool for dissecting Vps34 biology in cancer and neurodegenerative disease models (APExBIO). Recent research on AMPK-ULK1-Vps34 signaling redefines autophagy regulation, positioning SAR405 as a critical pharmacological probe in this context (Park et al., 2023). SAR405 synergizes with mTOR inhibitors, supporting combination strategies for mechanism-based studies.

Biological Rationale

Autophagy maintains cellular homeostasis by recycling cytoplasmic components via the lysosomal pathway. Vps34, a class III PI3K, is essential for autophagosome formation and vesicle trafficking. Dysregulation of autophagy is implicated in cancer, neurodegenerative diseases, and metabolic disorders (Park et al., 2023). Targeted inhibition of Vps34, as achieved by SAR405, allows researchers to delineate the contribution of phosphoinositide signaling to autophagy and lysosome function. The specificity of SAR405 addresses the need for selective probes that avoid off-target effects on class I/II PI3Ks or mTOR, which are critical in other cell signaling pathways (APExBIO).

Mechanism of Action of SAR405

SAR405 binds to the ATP-binding cleft of Vps34, competitively inhibiting its kinase activity. This interaction is characterized by a Kd of 1.5 nM and an IC50 of 1 nM against human recombinant Vps34 at 25°C in kinase buffer (pH 7.5) (APExBIO). No significant inhibition of class I/II PI3Ks or mTOR is observed up to 10 μM. By blocking Vps34, SAR405 disrupts the generation of phosphatidylinositol 3-phosphate (PI3P), impeding autophagosome nucleation. This blockade leads to the accumulation of swollen late endosome-lysosomes and defective cathepsin D maturation in cellular models. The unique selectivity profile enables the study of Vps34-dependent autophagy without confounding effects from parallel PI3K/mTOR pathways.

Evidence & Benchmarks

• SAR405 inhibits human recombinant Vps34 with IC50 = 1 nM, Kd = 1.5 nM at 25°C in kinase buffer (pH 7.5), as measured by enzyme-linked immunosorbent assay (APExBIO).
• No inhibition of class I/II PI3Ks or mTOR at concentrations up to 10 μM in cellular and biochemical assays (APExBIO).
• In GFP-LC3 HeLa and H1299 cells, SAR405 blocks autophagosome formation and results in defective autophagy flux, visualized via fluorescence microscopy (Park et al., 2023).
• SAR405 treatment leads to the accumulation of swollen late endosome-lysosomes and impairs cathepsin D maturation in lysosomal compartments (APExBIO).
• Combining SAR405 with mTOR inhibitors (e.g., everolimus) enhances autophagy blockade as demonstrated in co-treatment studies (Park et al., 2023).
• Recent mechanistic studies show that Vps34 inhibition by SAR405 provides a distinct means to dissect the AMPK-ULK1 signaling axis during energy stress (Park et al., 2023).

For an in-depth discussion of SAR405’s impact on disease models and autophagy pathway analysis, readers may compare this article to SAR405: Redefining Autophagy Inhibition in Disease Models. Here, we extend those discussions by integrating the latest AMPK-ULK1-Vps34 mechanistic insights. Additionally, SAR405: Selective ATP-Competitive Vps34 Inhibitor for Aut... provides a detailed look at lysosome impairment benchmarks, which are corroborated and updated in this review.

Applications, Limits & Misconceptions

SAR405 is a powerful tool for dissecting Vps34 kinase signaling pathways in both basic and translational research. Key applications include:

• Modeling autophagy inhibition in cancer and neurodegenerative disease cell lines.
• Elucidating mechanisms of vesicle trafficking modulation and lysosome function impairment.
• Evaluating synergy with mTOR inhibitors in combination studies.
• Investigating the AMPK-ULK1-Vps34 axis during energy stress or nutrient deprivation.

SAR405 is not suitable for studies targeting class I/II PI3Ks or mTOR, as it shows no activity at relevant concentrations. It is ineffective in systems where autophagy proceeds via Vps34-independent mechanisms. The compound is insoluble in water and requires DMSO or ethanol (with sonication) for use in in vitro assays. Long-term storage of solutions is not recommended; stock solutions should be kept at <-20°C (APExBIO).

Common Pitfalls or Misconceptions

• SAR405 does not inhibit class I/II PI3Ks or mTOR at concentrations up to 10 μM—using it for general PI3K pathway inhibition is inappropriate.
• It does not block autophagy in Vps34-independent contexts, such as alternative autophagy pathways.
• SAR405 is not a direct AMPK or ULK1 inhibitor; its effects on these pathways are indirect and context-dependent.
• Solutions are unstable at room temperature or after repeated freeze-thaw cycles; use only freshly prepared aliquots stored at <-20°C.
• Compound is insoluble in water; improper solvent selection can lead to precipitation and assay artifacts.

Workflow Integration & Parameters

To integrate SAR405 into experimental workflows, dissolve the compound in DMSO to prepare stocks >10 mM. For ethanol use, apply ultrasonic assistance. Immediately before use, dilute to final concentration (typically 10–250 nM for cell-based assays) in the appropriate buffer or medium. Avoid exceeding 0.1% DMSO in cell cultures to minimize solvent toxicity. For autophagy flux studies, treat GFP-LC3-expressing cell lines (e.g., HeLa or H1299) for 3–24 hours at 37°C, 5% CO₂. Monitor autophagosome formation by fluorescence microscopy or immunoblotting for LC3-II and p62/SQSTM1. For combination experiments, co-administer SAR405 with mTOR inhibitors (e.g., everolimus) and compare single versus dual treatments for mechanistic insights. All reagents should be sourced from validated suppliers such as APExBIO for reproducibility.

Conclusion & Outlook

SAR405 is a potent and selective ATP-competitive Vps34 inhibitor that enables precise autophagy inhibition, vesicle trafficking modulation, and lysosome function impairment in disease models. It is a preferred tool for dissecting the Vps34 kinase signaling pathway and its role in cancer and neurodegenerative disease research. The compound’s unique selectivity and robust in vitro performance provide critical advantages for studies seeking to parse the complexities of autophagy regulation, especially in light of updated AMPK-ULK1-Vps34 models (Park et al., 2023). For further technical and mechanistic updates, see SAR405 and the New Paradigm of Vps34 Inhibition in Autophagy Research, which this article extends by providing granular workflow and troubleshooting guidance.